Sponsor:
Regeneron Pharmaceuticals
Code:
NCT07410117
Conditions
Cancer-Associated Thrombosis (CAT)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
REGN7508
Placebo
Brief summary:
Conditions
Cancer-Associated Thrombosis (CAT)
Study ID
NCT07410117
Start date
Mar 9, 2026
Status verified date
May, 2026
Completion date
May 6, 2030
Anticipated
Primary completion date
Jan 23, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
1120 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: REGN7508
placebo comparator: Placebo
Interventions
REGN7508
Placebo
Primary outcome measure
Central contacts
Locations
Bioresearch Partner- Hialeah Hospital
Recruiting
Hialeah, Florida, United States, 33013
Helios Clinical Research
Recruiting
North Miami Beach, Florida, United States, 33169
El Paso Medical Research Institute (Medresearch Inc)
Recruiting
El Paso, Texas, United States, 79902
Sponsor
Regeneron Pharmaceuticals
Last update posted
Aug 20, 2026
Last verified
May, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-08-20.